The discovery of BMS-457, a potent and selective CCR1 antagonist.
about
Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.Synthesis and characterization of tritium labeled N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide.
P2860
The discovery of BMS-457, a potent and selective CCR1 antagonist.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@ast
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@en
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@nl
type
label
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@ast
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@en
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@nl
prefLabel
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@ast
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@en
The discovery of BMS-457, a potent and selective CCR1 antagonist.
@nl
P2093
P1476
The discovery of BMS-457, a potent and selective CCR1 antagonist
@en
P2093
Andrew J Tebben
Andrew Watson
Daniel S Gardner
Guchen Yang
Javed Khan
John Hynes
John V Duncia
P304
P356
10.1016/J.BMCL.2013.04.079
P407
P577
2013-05-07T00:00:00Z